Our approach can be defined as “biopolymer engineering” whereby, thanks to targeted chemical modification of the polymer chain, we are able to introduce specific molecular probes which initiate specific cellular responses.
The aim is to synergistically combine the anti-inflammatory activity with the regenerative capacity of natural biopolymers through the interaction of galectins, thus creating a new generation of bio-molecules intended for specific therapeutic applications.
SYNC-B3® is an abbreviation for Synergistic Non-crosslinked biopolymers and consists of highly tuneable bio-matrices made up of CHITLAC®, and other biomolecules, including hyaluronic acid. CHITLAC® is obtained from CHITOSAN (CS) through a process which allows a galactose moiety to be conjugated to the amino group of the polymer chain.
SYNC-B3® bio-matrices can also be conveniently used for the development of drug-carriers (e.g. low dose active ingredients) in different pharmaceutical compositions.
The interaction between CHITLAC®‘s galactose moiety and the galectin receptors (e.g. GAL-1, GAL-3) promotes the tuning of the expression of pro-inflammation factors and enables and promotes the tissue regeneration role played by natural biomolecules, such as hyaluronic acid.